Hirose S, Ravi L, Prince G M, Rosenfeld M G, Silber R, Andresen S W, Hazra S V, Medof M E
Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106.
Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6025-9. doi: 10.1073/pnas.89.13.6025.
To identify mannosyl (Man)-containing intermediates of the human glycoinositol phospholipid (GPI) anchor pathway and examine their expression in paroxysmal nocturnal hemoglobinuria (PNH), mannolipid products deriving from in vitro guanosine diphosphate [3H]Man labeling of HeLa cell microsomes were characterized. The defined GPI species were correlated with products deriving from in vivo [3H]Man labeling of normal and (GPI-anchor defective) affected leukocytes. In vitro analyses in HeLa cells showed dolichol-phosphoryl (Dol-P)-[3H]Man and a spectrum of [3H]Man lipids exhibiting TLC mobilities approximating those of Trypanosoma brucei (Tryp) GPI precursors. Iatrobead HPLC separations and partial characterizations of the major isolated [3H]Man species (designated H1-H8) showed that all but H1 (Dol-P-Man) were sensitive to HNO2 deamination and serum GPI-specific phospholipase D digestion but were resistant to phosphatidylinositol-specific phospholipase C digestion unless previously deacylated with mild alkali. [3H]Man label in H3, H4, and H6 but not in H5 or H7 was efficiently released into the aqueous phase by jack bean alpha-mannosidase digestion. BioGel P-4 and AX-5 sizing of the dephosphorylated core glycan fragments of H6 and H7 gave values that coincided precisely with the corresponding glycan fragments from the fully assembled Tryp anchor donor A' (P2). Affected leukocytes from four patients with PNH supported formation of GlcNAc- and GlcN-PI but all failed to express H6 and H7 as well as H8 and two showed complete absence of earlier Man-containing intermediates. These findings argue that human intracellular GPI mannolipids are built on acylated inositol phospholipids, that H6 and H7 contain differentially phosphoethanolamine-substituted Man3-GlcN-inositol cores, and that PNH cells are defective in conversion of GlcN-PI into these more mature mannolipid structures.
为鉴定人糖基磷脂酰肌醇(GPI)锚定途径中含甘露糖基(Man)的中间体,并检测其在阵发性夜间血红蛋白尿(PNH)中的表达,对源自体外[3H]甘露糖二磷酸鸟苷标记HeLa细胞微粒体的甘露糖脂产物进行了表征。确定的GPI种类与源自正常和(GPI锚定缺陷)受影响白细胞体内[3H]甘露糖标记的产物相关。HeLa细胞中的体外分析显示了多萜醇磷酸化(Dol-P)-[3H]甘露糖以及一系列[3H]甘露糖脂,其薄层层析迁移率接近布氏锥虫(Tryp)GPI前体。Iatrobead高效液相色谱分离及对主要分离出的[3H]甘露糖种类(命名为H1-H8)的部分表征表明,除H1(Dol-P-甘露糖)外,所有种类都对亚硝酸脱氨和血清GPI特异性磷脂酶D消化敏感,但对磷脂酰肌醇特异性磷脂酶C消化有抗性,除非先前用弱碱脱酰基。经刀豆α-甘露糖苷酶消化后,H3、H4和H6中的[3H]甘露糖标记能有效释放到水相中,而H5或H7中则不能。对H6和H7的去磷酸化核心聚糖片段进行BioGel P-4和AX-5尺寸排阻分析得到的值与完全组装的Tryp锚定供体A'(P2)的相应聚糖片段精确一致。来自4例PNH患者的受影响白细胞支持GlcNAc和GlcN-PI的形成,但均未能表达H6和H7以及H8,且有2例完全缺乏早期含甘露糖的中间体。这些发现表明,人细胞内GPI甘露糖脂是基于酰化肌醇磷脂构建的,H6和H7含有差异磷酸乙醇胺取代的Man3-GlcN-肌醇核心,且PNH细胞在将GlcN-PI转化为这些更成熟的甘露糖脂结构方面存在缺陷。